A clinical case controled for the intraocular tamponade material in the vitretomy for idiopathic macular hole.

A clinical case controled for the intraocular tamponade material in the vitretomy for idiopathic macular hole. - Macular hole tamponade study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006843

Enrollment

Registered

2011-12-15

Start date

2011-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic macular hole

Interventions

We replace vitreous with air at the end of surgery. The air tamponade will disappear applox. 7 days. We replace vitreous with SF6 at the end of surgery. The SF6 tamponade will disappear applox. 14 d

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The macular hole patients who consulted this hospital and meet following criterion. .A clinical record at the time of study entry contains no deficiency for essential points. .20 years old or older. .The affected eye can be evaluated with Gass' elassification of macular hole using Optical Coherence Tomography(OCT). .The affected eye should have no other clinically significant abnormality which may cause loss of vision.

Exclusion criteria

Exclusion criteria: .When the patient does not hope for entry. .In the case when there is a unpredicted worsening of the disease or advance event which the patient should exit this study.

Design outcomes

Primary

Measure	Time frame
We try to compare the improvement of macular hole closer rate and BCVA after vitrectomy at the point of 1.3. 6.12 month post operatively.	—

Countries

Japan

Contacts

Public ContactToshimitsu Ishiguro

Kansai Medical University Opthalmology Hirakata Hospital

0728040101

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026